- Published on
KembaraXtra-Medicine – Atrial Myxoma
Atrial myxoma is a benign neoplasm of mesenchymal origin and represents the most common primary tumor of the heart. Although histologically benign, atrial myxomas are clinically significant because their size, mobility, and intracardiac location can lead to serious and sometimes life-threatening complications. They are most commonly referred to as cardiac myxomas.
Primary cardiac tumors are extremely rare, with an autopsy prevalence ranging from 0.001% to 0.3%, and metastatic tumors occur far more frequently than primary tumors. Among primary cardiac tumors, myxomas account for 30% to 50% of benign cases. Approximately 65% occur in females. Most cases are sporadic, but 4.5% to 10% are familial, commonly associated with Carney complex. The median age of presentation is about 56 years, although familial cases tend to occur earlier, with an average age of 25 years. Most myxomas arise in the left atrium (about 75%), followed by the right atrium, right ventricle, and left ventricle. They are typically pedunculated and attached to the interatrial septum.
Histopathologically, atrial myxomas are characterized by abundant loose myxoid stroma containing scattered round, polygonal, or stellate cells with dense, irregular nuclei derived from multipotent mesenchymal cells. While benign in classification, myxomas can secrete cytokines and growth factors, contributing to systemic and constitutional symptoms in addition to mechanical complications.
Clinically, patients with atrial myxomas usually present in one of three ways: atrioventricular valve obstruction, systemic embolization, or constitutional symptoms. Obstructive symptoms may mimic mitral or tricuspid valve disease and include dyspnea, orthopnea, paroxysmal nocturnal dyspnea, syncope, dizziness, edema, atrial fibrillation, or rarely sudden death. Symptoms that vary with body position, particularly improvement when recumbent, are suggestive. Systemic embolization occurs in nearly one third of patients and may manifest as stroke, pulmonary embolism, paradoxical embolism, or acute coronary syndrome. Constitutional features such as fever, weight loss, arthralgia, and Raynaud phenomenon are also common, while rare presentations include peripheral neuropathy, vasculitis, or paraneoplastic syndromes. On examination, findings may include murmurs, signs of pulmonary hypertension, a widely split first heart sound, or a characteristic early diastolic “tumor plop.”
Most atrial myxomas are sporadic, but familial cases are commonly associated with Carney complex, an autosomal dominant condition characterized by cardiac and extracardiac myxomas, pigmented skin lesions, endocrine hyperactivity, and other tumors such as schwannomas. Multiple genetic loci and mutations have been identified in this syndrome.
Diagnosis requires a high index of suspicion due to nonspecific symptoms that overlap with many cardiovascular and pulmonary conditions. Laboratory tests may show anemia, thrombocytopenia, elevated inflammatory markers, increased immunoglobulins, or elevated cardiac biomarkers, though these findings are nonspecific. Electrocardiography may reveal atrial enlargement, arrhythmias, or conduction abnormalities. Transthoracic echocardiography is the initial diagnostic test of choice, with approximately 95% sensitivity, while transesophageal echocardiography approaches 100% sensitivity and better defines tumor attachment and mobility. CT and MRI are valuable for delineating tumor size, extension, vascularity, and for distinguishing myxoma from atrial thrombus. Cardiac catheterization may demonstrate neovascularization and is sometimes used to assess for concomitant coronary artery disease before surgery.
The definitive treatment for atrial myxoma is prompt surgical excision, which should not be delayed due to the risk of embolization or sudden death. Postoperatively, arrhythmias or conduction disturbances may occur and are managed accordingly. In rare cases, particularly with recurrent tumors associated with Carney complex, advanced surgical approaches such as cardiac autotransplantation or transplantation may be required.
Prognosis after surgical excision is excellent, with reported survival rates of approximately 95% at three years. However, recurrence can occur in up to 5% of sporadic cases and up to 20% of familial cases, particularly within the first six years. Risk factors for recurrence include familial disease, atypical tumor location, and multicentric tumors. Malignant transformation into atrial myxofibrosarcoma, although rare, should be considered in cases of early recurrence. Untreated atrial myxomas carry a significant risk of sudden death, estimated at up to 15%.
Referral to a cardiologist is recommended for diagnosis and management, and once identified, early consultation with a cardiovascular surgeon is essential. Long-term follow-up with periodic echocardiography is advised to monitor for recurrence, especially in patients with familial disease or Carney complex.
Atrial myxoma is a benign neoplasm of mesenchymal origin and represents the most common primary tumor of the heart. Although histologically benign, atrial myxomas are clinically significant because their size, mobility, and intracardiac location can lead to serious and sometimes life-threatening complications. They are most commonly referred to as cardiac myxomas.
Primary cardiac tumors are extremely rare, with an autopsy prevalence ranging from 0.001% to 0.3%, and metastatic tumors occur far more frequently than primary tumors. Among primary cardiac tumors, myxomas account for 30% to 50% of benign cases. Approximately 65% occur in females. Most cases are sporadic, but 4.5% to 10% are familial, commonly associated with Carney complex. The median age of presentation is about 56 years, although familial cases tend to occur earlier, with an average age of 25 years. Most myxomas arise in the left atrium (about 75%), followed by the right atrium, right ventricle, and left ventricle. They are typically pedunculated and attached to the interatrial septum.
Histopathologically, atrial myxomas are characterized by abundant loose myxoid stroma containing scattered round, polygonal, or stellate cells with dense, irregular nuclei derived from multipotent mesenchymal cells. While benign in classification, myxomas can secrete cytokines and growth factors, contributing to systemic and constitutional symptoms in addition to mechanical complications.
Clinically, patients with atrial myxomas usually present in one of three ways: atrioventricular valve obstruction, systemic embolization, or constitutional symptoms. Obstructive symptoms may mimic mitral or tricuspid valve disease and include dyspnea, orthopnea, paroxysmal nocturnal dyspnea, syncope, dizziness, edema, atrial fibrillation, or rarely sudden death. Symptoms that vary with body position, particularly improvement when recumbent, are suggestive. Systemic embolization occurs in nearly one third of patients and may manifest as stroke, pulmonary embolism, paradoxical embolism, or acute coronary syndrome. Constitutional features such as fever, weight loss, arthralgia, and Raynaud phenomenon are also common, while rare presentations include peripheral neuropathy, vasculitis, or paraneoplastic syndromes. On examination, findings may include murmurs, signs of pulmonary hypertension, a widely split first heart sound, or a characteristic early diastolic “tumor plop.”
Most atrial myxomas are sporadic, but familial cases are commonly associated with Carney complex, an autosomal dominant condition characterized by cardiac and extracardiac myxomas, pigmented skin lesions, endocrine hyperactivity, and other tumors such as schwannomas. Multiple genetic loci and mutations have been identified in this syndrome.
Diagnosis requires a high index of suspicion due to nonspecific symptoms that overlap with many cardiovascular and pulmonary conditions. Laboratory tests may show anemia, thrombocytopenia, elevated inflammatory markers, increased immunoglobulins, or elevated cardiac biomarkers, though these findings are nonspecific. Electrocardiography may reveal atrial enlargement, arrhythmias, or conduction abnormalities. Transthoracic echocardiography is the initial diagnostic test of choice, with approximately 95% sensitivity, while transesophageal echocardiography approaches 100% sensitivity and better defines tumor attachment and mobility. CT and MRI are valuable for delineating tumor size, extension, vascularity, and for distinguishing myxoma from atrial thrombus. Cardiac catheterization may demonstrate neovascularization and is sometimes used to assess for concomitant coronary artery disease before surgery.
The definitive treatment for atrial myxoma is prompt surgical excision, which should not be delayed due to the risk of embolization or sudden death. Postoperatively, arrhythmias or conduction disturbances may occur and are managed accordingly. In rare cases, particularly with recurrent tumors associated with Carney complex, advanced surgical approaches such as cardiac autotransplantation or transplantation may be required.
Prognosis after surgical excision is excellent, with reported survival rates of approximately 95% at three years. However, recurrence can occur in up to 5% of sporadic cases and up to 20% of familial cases, particularly within the first six years. Risk factors for recurrence include familial disease, atypical tumor location, and multicentric tumors. Malignant transformation into atrial myxofibrosarcoma, although rare, should be considered in cases of early recurrence. Untreated atrial myxomas carry a significant risk of sudden death, estimated at up to 15%.
Referral to a cardiologist is recommended for diagnosis and management, and once identified, early consultation with a cardiovascular surgeon is essential. Long-term follow-up with periodic echocardiography is advised to monitor for recurrence, especially in patients with familial disease or Carney complex.
0 Comments
